Key Highlights
- Oxford Nanopore Technologies (LSE:ONT) fell 4.58% to 200.00p on Friday 16 October 2026, the worst performer in the FTSE 250.
- No new company announcement accompanied the drop, and market commentators pointed to profit-taking and pressure on tech-linked growth stocks.
- The shares had rallied strongly from lows near 96p over the past year, trading above 215p earlier in October.
- Recent news includes a European patent injunction against MGI and a £21m partial stake sale by IP Group.
- The company targets adjusted EBITDA breakeven in 2027.
Why Oxford Nanopore Is Trending Today
Oxford Nanopore Technologies (LSE:ONT) was the biggest faller in the FTSE 250 on Friday 16 October 2026, dropping 4.58% to close at 200.00p. The decline stood out on a day when the wider market was firm. The FTSE 250 rose 0.45% to 24,533.90 and the FTSE 100 gained 0.38% to 10,881.90, completing its best week in around six months.
There was no fresh trading update or regulatory filing to explain the fall. Instead, market commentators linked it to the rotation that dominated the week. A global sell-off in AI and semiconductor stocks, triggered by fears of competition in memory chips and hot US inflation data, prompted investors to move out of technology-linked growth names and into defensive sectors such as defence, tobacco and consumer staples. Loss-making, high-valuation companies like Oxford Nanopore are particularly sensitive to that shift and to rising bond yields, and UK interest rate expectations remain in focus ahead of next week's inflation data.
Profit-taking also played a part. The shares had risen strongly from a 12-month low of around 96p, and directors bought shares through the company's share incentive plan at about 215p on 14 October. Friday's close brings the stock back to the round 200p level, which some traders treat as a key support point.
Business Overview
Oxford Nanopore, based in Oxford, develops DNA and RNA sequencing technology. Its nanopore platform reads long strands of genetic material in real time, using devices ranging from the pocket-sized MinION to high-throughput PromethION systems. Customers include academic researchers, biopharma companies, clinical laboratories and public health bodies, and the company sells consumables such as flow cells as well as instruments.
The business has grown revenue quickly but remains loss-making. In its 2025 results, revenue rose about 22% to £223.9m while adjusted losses narrowed. In March 2026 the company forecast constant currency revenue growth of 21% to 25% for both 2026 and 2027, trimming its earlier 2027 range, and reiterated targets for adjusted EBITDA breakeven in 2027 and cash breakeven by 2028.
A Volatile Year
Oxford Nanopore (LSE:ONT) has had a turbulent 2026. In the summer it warned that first-half revenue would come in below expectations, citing weaker sales in China linked to export controls, lower Middle East sales and order timing in the Americas, and the shares fell sharply. Interim results in August showed a narrower loss, improved gross margins and maintained full-year guidance, which helped the shares recover strongly.
More recently, the company secured a preliminary injunction from the Munich Local Division of the Unified Patent Court against MGI Tech, covering certain MGI sequencing systems in several European markets including Germany, France and the UK. Oxford Nanopore said it would seek a permanent injunction, with a full trial expected in 2027. On 2 October, IP Group sold 10 million shares, worth about £21m, but retained a direct stake of around 7.2% and agreed a 90-day lock-up on its remaining holding.
Analyst View
Brokers are broadly positive but divided on valuation. Analyst tracking shows most covering brokers rate the stock a buy, with Peel Hunt at hold. Berenberg cut its target to 200p in August while keeping a buy rating, and JPMorgan raised its target to 220p. With the shares having risen through many of those targets in early October, some pullback was arguably unsurprising.
Risks and What Investors Are Watching Next
Key risks include the pace of revenue growth, exposure to China and US research funding, competition from larger sequencing rivals, and the timing of the path to profitability. As a growth stock, Oxford Nanopore (LSE:ONT) is also vulnerable to changes in interest rate expectations and sentiment towards technology.
Investors will watch for any further detail on the MGI patent case, progress in clinical and biopharma markets, and evidence that second-half revenue is tracking the 21% to 25% growth guidance, including expected collaboration and licensing income. UK inflation data next week and the Budget on Wednesday 28 October 2026 could influence rate expectations and appetite for FTSE 250 growth stocks. The next major company update is likely to be a full-year trading statement early in 2027.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...